ArticlePloS one2026
Integrative multi-omics and network-based machine learning for early diagnosis of Parkinson's disease.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genetic architecture and molecular pathogenesis of Parkinson's disease: emerging mechanisms and therapeutic targets.Metabolic brain disease · 2026Review
- Dysregulation of the Extracellular Matrix in the Synaptic Pathology of Parkinson's Disease: Molecular Mechanisms and Novel Therapeutic Approaches.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate diagnosis of Parkinson's Disease (PD) remains challenging due to its biological complexity. Integrating machine learning with multi-omics and network topological analyses may enhance diagnostic precision.
objectiveTo classify early-stage PD patients and healthy controls (HCs) by integrating multi-omics data and network-based machine learning.
methodsWe analyzed 305 participants from the PPMI cohort (213 PD, 92 HCs) using DNA methylation, gene expression, and proteomic data. Feature selection was conducted through sPLS-DA, followed by integration via DIABLO. Regulatory gene networks were constructed using STRING-based topology analysis. An XGBoost classifiers were trained and optimized on 244 samples and validated on 61 independent samples. Furthermore, we conducted external validation using data from 26 participants (12 PD, 14 HCs) in the GEO dataset, incorporating DNA methylation and gene expression profiles.
resultsDIABLO-based integration identified 56 CpG sites, 61 genes, and 70 proteins. Network topology analysis revealed 59 key regulators. Among three XGBoost models-based on multi-omics signatures, topological regulators, and their combination-the multi-omics model achieved the best test-set performance (AUC 0.72, 95%CI 0.51-0.85, accuracy 0.74, 95%CI 0.61-0.82). Within the validation set, the topological regulators model achieved the superior performance (AUC 0.57, 95%CI 0.37-0.73, accuracy 0.62, 95%CI 0.38-0.73).
conclusionCombining machine learning with integrative multi-omics and network topology analysis enables effective biomarker identification and PD classification, with strong potential for clinical diagnostic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.